Literature DB >> 2182337

Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice.

E Handman1, L L Button, R W McMaster.   

Abstract

The Mr 63,000 membrane polypeptide (gp63) is one of the Leishmania receptors for host macrophages and has been shown to protect mice from infection. The gene encoding gp63, the major Mr 63,000 surface glycoprotein of L. major promastigotes, has been expressed as a fusion protein with the enzyme glutathione S- transferase encoded by the parasitic helminth Schistosoma japonicum. This fusion protein was recognized by polyclonal antibodies to the native Leishmania gp63 polypeptide. The insoluble gp63 fusion protein was purified by SDS-PAGE and electroelution and was used to raise antibodies in rabbits. These rabbit anti-gp63 antibodies recognized the fusion protein and the denatured parasite gp63 on immunoblots and by immunofluorescence on fixed promastigotes, but did not recognize the native molecule on live organisms. However, antibodies raised against native promastigote glycoproteins, affinity purified on solid-phase gp63 fusion protein, recognized both native and denatured gp63, suggesting the presence of native determinants in the recombinant protein. The gp63 fusion protein did not protect mice of either healer or nonhealer phenotype from challenge infection with live promatigotes. The implications of these results for the engineering of recombinant DNA-produced molecular vaccines are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2182337     DOI: 10.1016/0014-4894(90)90127-x

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  12 in total

1.  Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response.

Authors:  S Farajnia; F Mahboudi; S Ajdari; N E Reiner; A Kariminia; M H Alimohammadian
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Naive human T cells develop into Th1 effectors after stimulation with Mycobacterium tuberculosis-infected macrophages or recombinant Ag85 proteins.

Authors:  D M Russo; N Kozlova; D L Lakey; D Kernodle
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 3.  Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.

Authors:  Malcolm S Duthie; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

4.  Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.

Authors:  Tejinder Kaur; Ankita Thakur; Sukhbir Kaur
Journal:  J Parasit Dis       Date:  2012-09-06

5.  Characterization of an I-E-restricted, gp63-specific, CD4-T-cell clone from Leishmania major-resistant C3H mice that secretes type 2 cytokines and exacerbates infection with L. major.

Authors:  Cynthia M Theodos; Robin V Morris; Jeanette V Bishop; Jeremy D Jones; W Robert McMaster; Richard G Titus
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

6.  Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Authors:  D McMahon-Pratt; D Rodriguez; J R Rodriguez; Y Zhang; K Manson; C Bergman; L Rivas; J F Rodriguez; K L Lohman; N H Ruddle
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

7.  gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

Authors:  Swati Bhowmick; Rajesh Ravindran; Nahid Ali
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

8.  Leishmania surface protein gp63 binds directly to human natural killer cells and inhibits proliferation.

Authors:  T Lieke; S Nylén; L Eidsmo; W R McMaster; A M Mohammadi; A Khamesipour; L Berg; H Akuffo
Journal:  Clin Exp Immunol       Date:  2008-08       Impact factor: 4.330

9.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

10.  Protective immunity and vaccination against cutaneous leishmaniasis.

Authors:  Ifeoma Okwor; Zhirong Mou; Dong Liu; Jude Uzonna
Journal:  Front Immunol       Date:  2012-05-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.